Abstract
A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating from 0.5 to 4.0 mg kg–1. During all IHP procedures, leakage of perfusate was monitored. Duration of IHP was aimed at 60 min, but was shortened in eight cases as a result of leakage from the isolated circuit. From these, three patients developed WHO grade 3–4 leukopenia and two patients died due to sepsis. A reversible elevation of liver enzymes and bilirubin was seen in the majority of patients. Only one patient was treated with 4.0 mg kg–1L-PAM, who died 8 days after IHP as a result of multiple-organ failure. A statistically significant correlation was found between the dose of L-PAM, peak L-PAM concentrations in perfusate (R = 0.86, P≤ 0.001), perfusate area under the concentration-time curve (AUC; R = 0.82, P< 0.001), tumour tissue concentrations of L-PAM (R = 0.83, P = 0.011) and patient survival (R = 0.52, P = 0.02). The peak L-PAM concentration and AUC of L-PAM in perfusate at dose level 3.0 mg kg–1(n = 5) were respectively 35- and 13-fold higher than in the systemic circulation, and respectively 30- and 5-fold higher than reported for high dose oral L-PAM (80–157 mg m–2) and autologous bone marrow transplantation. Median survival after IHP (n = 21) was 19 months and the overall response rate was 29% (17 assessable patients; one complete and four partial remissions). Thus, the maximally tolerated dose of L-PAM delivered via IHP is approximately 3.0 mg kg–1, leading to high L-PAM concentrations at the target side. Because of the complexity of this treatment modality, IHP has at present no place in routine clinical practice. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aigner KR, Walther H and Link KH (1988) Isolated liver perfusion with MMC/5-FU: surgical technique, pharmacokinetics, clinical results. Contr Oncol 29: 229–246
Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T and Rosenberg SA (1998) Isolated hepatic perfusion with tumour necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479–1489
Borel Rinkes IHM, de Vries MR, Jonker AM, Swaak TJ, Hack CE, Nooyen PT, Wiggers T and Eggermont AMM (1997) Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br J Cancer 75: 1447–1453
Boros L, Peng YM, Alberts DS, Asbury RF, Goodman TL, Penn TE and Hickox DE (1990) Pharmacokinetics of very high-dose oral melphalan in cancer patients. Am J Clin Oncol 13: 19–22
Chang SY, Alberts DS, Farquhar D, Melnick LR, Walson PD and Salmon SE (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67: 682–684
Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem LJ and Bitran JD (1989) Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res 49: 1318–1321
Curley SA, Newman RA, Dougherty TB, Fuhrman GM, Stone DL, Mikolajek JA, Guercio S, Guercio A, Carrasco CH and Kuo MT (1994) Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1: 389–399
Garcia ST, McQuillan A and Panasci L (1988) Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochem Pharmacol 37: 3189–3192
Hafstrom LR, Holmberg SB, Naredi PL, Lindner PG, Bengtsson A, Tidebrant G and Schersten TS (1994) Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3: 103–108
Kemeny N (1995) Regional chemotherapy of colorectal cancer. Eur J Cancer 31A: 1271–1276
Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S and Bertino JR (1994) Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12: 2288–2295
Klaase JM, Kroon BB, Beijnen JH, van Slooten GW and van Dongen JA (1994) Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 70: 151–153
Leff RS, Thompson JM, Johnson DB, Mosley KR, Daly MB, Knight WA, Ruxer RL and Messerschmidt GL (1986) Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol 4: 1586–1591
Marinelli A, Dijkstra FR, van Dierendonck JH, Kuppen PJK, Cornelisse CJ and van de Velde CJH (1991 a) Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. Br J Cancer 64: 74–78
Marinelli A, van Dierendonck JH, van Brakel GM, Irth H, Kuppen PJK, Tjaden UR and van de Velde CJH (1991 b) Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 64: 1069–1075
Marinelli A, de Brauw LM, Beerman H, Keizer HJ, van Bockel JH, Tjaden UR and van de Velde CJH (1996) Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 26: 341–350
Meta Analysis Group in Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252–258
Oldhafer KJ, Lang H, Frerker M, Moreno L, Chavan A, Flemming P, Nadalin S, Schmoll E and Pichlmayr R (1998) First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 126: 622–631
Ravikumar TS, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, Hendler R, Hanna J and D’Andrea E (1994) Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumours. J Clin Oncol 12: 2723–2736
Runia RD, de Brauw LM, Kothuis BJ, Pauwels EK and van de Velde CJH (1987) Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 14: 113–118
Vahrmeijer AL, van Dierendonck JH and van de Velde CJH (1995) Treatment of colorectal cancer metastases confined to the liver. Eur J Cancer 31A: 1238–1242
Vahrmeijer AL, Snel CA, Steenvoorden DP, Beijnen JH, Pang KS, Schutrups J, Tirona R, Keizer HJ, van Dierendonck JH, van de Velde CJH and Mulder GJ (1996) Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans. Cancer Res 56: 4709–4714
van Ijken MGA, de Bruijn EA, de Boeck G, ten Hagen TLM, van der Sijp JRM and Eggermont AMM (1998) Isolated hypoxic hepatic perfusion with tumour necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 228: 763–770
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Vahrmeijer, A., van Dierendonck, J., Keizer, H. et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 82, 1539–1546 (2000). https://doi.org/10.1054/bjoc.2000.1175
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1175
Keywords
This article is cited by
-
Anästhesiologisches und postinterventionelles Management bei perkutaner hepatischer Melphalanperfusion (Chemosaturation)
Die Anaesthesiologie (2023)
-
Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies
CardioVascular and Interventional Radiology (2016)
-
Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
Advances in Therapy (2016)
-
Retrograde-outflow percutaneous isolated hepatic perfusion using cisplatin: A pilot study on pharmacokinetics and feasibility
European Radiology (2015)
-
Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model
European Radiology (2010)